Literature DB >> 16965940

Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation.

Nicolas Noiseux1, Massimiliano Gnecchi, Marco Lopez-Ilasaca, Lunan Zhang, Scott D Solomon, Arjun Deb, Victor J Dzau, Richard E Pratt.   

Abstract

We previously reported that intramyocardial injection of bone marrow-derived mesenchymal stem cells overexpressing Akt (MSC-Akt) efficiently repaired infarcted rat myocardium and improved cardiac function. Controversy still exists over the mechanisms by which MSC contribute to tissue repair. Herein, we tested if cellular fusion of MSC plays a determinant role in cardiac repair. We injected MSC expressing Cre recombinase, with or without Akt, into Cre reporter mice. In these mice, LacZ is expressed only after Cre-mediated excision of a loxP-flanked stop signal and is indicative of fusion. MSC engraftment within infarcted myocardium was transient but significantly enhanced by Akt. MSC fusion with cardiomyocytes was observed as early as 3 days, but was infrequent, and we found a low rate of differentiation of MSC into cardiomyocytes. MSC-Akt decreased infarct size at 3 days and restored early cardiac function. In conclusion, MSC-Akt improved early repair despite transient engraftment, low levels of cellular fusion, and differentiation. These new observations further confirm our recently reported data that early paracrine mechanisms mediated by MSC are responsible for enhancing the survival of existing myocytes and that Akt could alter the secretion of various cytokines and growth factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965940     DOI: 10.1016/j.ymthe.2006.05.016

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  168 in total

1.  Generation of human adult mesenchymal stromal/stem cells expressing defined xenogenic vascular endothelial growth factor levels by optimized transduction and flow cytometry purification.

Authors:  Uta Helmrich; Anna Marsano; Ludovic Melly; Thomas Wolff; Liliane Christ; Michael Heberer; Arnaud Scherberich; Ivan Martin; Andrea Banfi
Journal:  Tissue Eng Part C Methods       Date:  2011-12-19       Impact factor: 3.056

2.  A Cre-Lox P recombination approach for the detection of cell fusion in vivo.

Authors:  Anthony J Sprangers; Brian T Freeman; Nicholas A Kouris; Brenda M Ogle
Journal:  J Vis Exp       Date:  2012-01-04       Impact factor: 1.355

Review 3.  Cardiac cell therapy: boosting mesenchymal stem cells effects.

Authors:  E Samper; A Diez-Juan; J A Montero; P Sepúlveda
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 4.  Genetic engineering of mesenchymal stem cells and its application in human disease therapy.

Authors:  Conrad P Hodgkinson; José A Gomez; Maria Mirotsou; Victor J Dzau
Journal:  Hum Gene Ther       Date:  2010-10-22       Impact factor: 5.695

Review 5.  De novo myocardial regeneration: advances and pitfalls.

Authors:  Khawaja Husnain Haider; Stephanie Buccini; Rafeeq P H Ahmed; Muhammad Ashraf
Journal:  Antioxid Redox Signal       Date:  2010-10-12       Impact factor: 8.401

Review 6.  The paracrine effect: pivotal mechanism in cell-based cardiac repair.

Authors:  Simon Maltais; Jacques P Tremblay; Louis P Perrault; Hung Q Ly
Journal:  J Cardiovasc Transl Res       Date:  2010-06-08       Impact factor: 4.132

7.  Mesenchymal stem cells or cardiac progenitors for cardiac repair? A comparative study.

Authors:  Remco Koninckx; Annick Daniëls; Severina Windmolders; Françoise Carlotti; Urbain Mees; Paul Steels; Jean-Luc Rummens; Marc Hendrikx; Karen Hensen
Journal:  Cell Mol Life Sci       Date:  2010-10-24       Impact factor: 9.261

Review 8.  Mesenchymal stem cells in the pathogenesis and therapy of breast cancer.

Authors:  Christelle P El-Haibi; Antoine E Karnoub
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-12-21       Impact factor: 2.673

9.  Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells.

Authors:  Qiang Xiong; Lei Ye; Pengyuan Zhang; Michael Lepley; Cory Swingen; Liying Zhang; Dan S Kaufman; Jianyi Zhang
Journal:  Circ Res       Date:  2012-06-21       Impact factor: 17.367

10.  Donor mesenchymal stromal cells (MSCs) undergo variable cardiac reprogramming in vivo and predominantly co-express cardiac and stromal determinants after experimental acute myocardial infarction.

Authors:  Gustavo Yannarelli; James N Tsoporis; Jean-Francois Desjardins; Xing Hua Wang; Ali Pourdjabbar; Sowmya Viswanathan; Thomas G Parker; Armand Keating
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.